C-MET & HGF Inhibitor Market

Key data points: Market size in 2027 = $8.3 billion and 2035 = $49.1 billion, growth forecast = 24.8% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in C-MET & HGF inhibitor market to 2035 by type (cabozantinib, crizotinib, tepotinib, and others), application (hospital and drug store), and region (North America, Europe, Asia Pacific, and the Rest of the World) C-MET & HGF Inhibitor Market The future of the global C-MET & HGF inhibitor market looks promising with opportunities in the hospital and drug store markets. The global C-MET & HGF inhibitor market is expected to reach an estimated $49.1 billion by 2035 from $8.3 billion in 2027 with a CAGR of 24.8% from 2027 to 2035. The major drivers for this market are the increasing incidence of cancer cases, the rising need for targeted cancer therapies, and the growing focus on precision medicine approaches. • Lucintel forecasts that, within the type category, cabozantinibm is expected to witness the highest growth over the forecast period due to wide efficacy of cabozantinib against several cancer types. • Within the application category, hospital is expected to witness higher growth over the forecast period due to trend of hospital-based cancer care to include the use of targeted cancer therapies. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to higher cancer diagnosis rates, and increased access to targeted cancer therapies. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in C-MET & HGF Inhibitor Market C-Met & HGFI inhibitors, from 2025 to 2027, are expected to shift from broad oncology research to sophisticated drug development. Improved positions in the clinic through the combination of other agents and companion diagnostics, have been noted by various sources. The Lucintel report maintains that commercial reality and variability of regulation will govern the market. • Biomarker Precision: The identification of MET exon 14 skipping mutations in NSCLC is common and the FDA has approved and/or released label expansions for select CML inhibitors. The next several years will determine how these therapies are prescribed. • Selective Inhibition: It is generally accepted in the field that high selectivity for c-MET is critical for therapeutic use. There are a number of agents with activity against c-MET, however, the focus is on agents with activity against other tumour pathways. • Combination Therapy: Preclinical and clinical data supports the combination of MET pathway inhibitors and other pathway inhibitors and chemotherapeutic agents. There are a number of ongoing clinical trials that will likely improve the clinical utility of MET pathway inhibitors. • Safety-led Differentiation: Unrelated adverse effects of peripheral edema and gastrointestinal issues and liver function test abnormalities continue to lead to the discontinuation of therapy. Companies have shifted their focus to optimizing pharmacology. Products with less treatment disruptions will be more attractive, especially for chronic indications. • Regional Commercialization: There are country-level variations in drug approvals and reimbursement processes. Companies strategically time product launches according to local variations. For example, the 2025 Oncology policy in China has accelerated local adoption of oncology therapeutics. Varying levels of evidence and different standards across countries will shape the global product uptake and revenue stream until 2030. The ability of a therapy to effectively and durably block the target MET receptor will become more valuable than the use of surrogate inhibitors. As combination therapies become more common, companies that have valuable and accessible combination products and companion diagnostics, will be more competitive. Important therapeutic opportunities and unmet needs for difficult to treat cancers will support investment and M&A activities. Recent Developments in the C-MET & HGF Inhibitor Market Market activity in the C-MET and HGF inhibitor market picked up from 2021 to 2025, with the completion of Biomarker-led trials, entering into partnerships and reaching regulatory decisions. From 2025 to 2027, Lucintel predicts the market will continue to grow and advance, with companies focusing on the same types of receptor tyrosine kinases (RTKs). However, during this time, companies will also advance the field by utilizing different strategies and approaches. • Regulatory Approval: In May 2025, the FDA granted Accelerated Approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of non-squamous NSCLC that is un-resectable and/or metastatic. Emrelis is the first antibody drug conjugate to receive marketing authorization, and will likely stimulate the interest and impact the field of c-MET testing for at least the next 3-5 years. • Biomarker: In the case of telisotuzumab vedotin-tllv (Emrelis), the FDA approved the drug using a c-MET protein expression frame work, which is broader and encompassing than MET Exon 14 skipping. AbbVie reported that the pivotal LUMINOSITY Trial had an overall response rate of 35%. The commercial success of Emrelis will be dependent on the standardization and availability of testing and pathology frame work. • Combination Development: In addition to continuing to study pembrolizumab in combination with c-MET pathway-related interventions, Merck evaluated other combination studies during the period. For instance, they initiated multiple studies to evaluate the use of pembrolizumab in combination with other anti-cancer therapies and also established a collaboration with Genentech for the study of pembrolizumab in combination with anti-PD-L1 and other oncology therapies. While safety and efficacy will ultimately dictate the pace of adoption, the rationale supporting the use of combination therapies is strong and will likely drive the field. • Pipeline Competition: Savolitinib is currently the only selective inhibitor of MET that is in clinical development. As such, the competition that this therapy will face is likely to come from other ADCs. Pricing and reimbursement policies will likely differ for each of these therapies, and the potential benefits for patients with MET exon 14 alterations will likely vary based on the selective inhibitor versus ADC. • Manufacturing: There has been a proliferation of contracts for the manufacture of Antibody Drug Conjugates, and financing for similar projects has increased. New, larger ADC manufacturing facilities will help ease the current limitations in supply of these products and improve access for various cancer indications. Precision oncology will remain a distinct area of focus in oncology, and the approval of Emrelis will facilitate the use of c-MET inhibitors for select cancer patients. Beyond 2026, the focus will remain on the integration of multiple therapies and the progressive advancement of technologies to facilitate safe, reliable and continuous care for patients. The outcome of clinical studies will be the main driver for market share. Strategic Growth Opportunities in the C-MET & HGF Inhibitor Market The C-MET and HGF inhibitors market has recently gained momentum with improvements in biomarker testing and the elucidation of resistance mechanisms by the biopharmaceutical industry. During the 2024-2026 period, Lucintel anticipates the monopoly situation in the market will improve with the introduction of differentiated regimens, flexible pharmaceutical distribution models, and diagnostic-led indications. • Resistance-controlling Combinations: Currently, the most well-advanced resistance-controlling combination is the use of a c-MET inhibitor in conjunction with an EGFR inhibitor for the treatment of patients with non-small cell lung cancer (NSCLC) who have developed resistance to EGFR-targeted therapy. In February 2025, the VISION study of tiptoeing included 313 patients with met exclusion 14 NSCLC. Development of resistance combining inhibitors of receptor tyrosine kinases extends the duration of therapy and protects and/or extends the period of inhibition of receptor tyrosine kinases. • Expanded Companion Diagnostics: A greater availability of liquid biopsy tests will aid in the detection of MET gene amplification and other alterations, including MET exon 14, in the presence of an inadequate tumour sample. The FDA reviewed 20 liquid biopsy tests for cancer in January 2025. • Premium Oral Formulation: Strong product differentiation is found in tablets that, for example, allow once-a-day dosing. These tablets are more expensive, as less restrictive requirements for food intake before dosing, and fewer required medical supervision, increase the tolerability of the product. In Japan, oncology products exceeded ¥1 trillion in sales in 2025, and products that enhance adherence and address toxicities will take larger portions of the market. • Emerging Market Expansion: New product launches in MET inhibitor oncology will occur in newer, growing markets like China, India and Southeast Asia and Latin America. Of these markets, China is most competitive. There were over 5,000 oncology clinical trials sanctioned by the Chinese FDA in 2025. Even so, the cost of clinical development remains high, and local regulatory and clinical environments constrain rapid development. • C-MET Inhibitor Combinations: Beyond lung cancers, C-MET inhibitors will be combined with other agents, and additional indications in other cancers will be defined. With 900,000 cases estimated for 2025, liver cancers remain an unmet need, and in combination with other agents, they may be targeted. Indiscriminate product prescribing will not be the strongest driver for market growth. True breakthroughs will occur with novel ways to integrate diagnostics for personalized oncology products. Strong, strategic alliances will accelerate market access and product commercialization, particularly in oncology. C-MET & HGF Inhibitor Market Drivers and Challenges The market for c-met and HGF inhibitors is advancing due to developments in precision oncology, increase in cancer cases, and supportive regulations by authorities. Pharmaceutical companies are interested in the field, and biomarker tests are improving. Cyclic changes in the economy impact the type of oncology treatments that are commercially available. Stringent regulatory authorities are initially approving more biomarker-based therapies. Lucintel is cautiously optimistic about the market. The factors responsible for driving this market include: • Growing Precision Oncology Demand: An increasing demand for precision oncology has led to the identification of various cancer cases due to c-met pathway activation. It has been observed that tumors overexpressing c-met are often unresponsive to various anti-EGFR therapies. Various pharmaceutical companies have shown interest in developing anti-c-met therapies. The U.S. FDA granted accelerated approval to telisotuzumab vedotin for select cases of non-small cell lung cancer in May 2025. This favorable regulatory decision is expected to stimulate the use of c-met targeted therapies in various cancers. It is expected that in the next 5 years, targeted therapies against the c-met pathway will be used to treat gastric, liver, and other cancers. • Improvements in Technology: The development of more effective small-molecule inhibitors and antibody-based platforms may allow the blocking of c-MET and HGF pathways. Innovations in antibody-drug conjugates and bispecific antibodies may facilitate the development of more potent and efficacious therapies against resistant tumors. Examples of advancements in this area include the U.S. FDA’s approval of telisotuzumab vedotin in May 2025. In the next 3 to 5 years, more potent therapies, including combination therapies, may be developed, particularly against cancers for which effective treatments are lacking. Additionally, ongoing studies may facilitate the development of therapies against cancers of high unmet medical need and provide response data for cancers for which c-MET and HGF pathways are activated. • Positive Changes in Drug Development: Improvements in the U.S. Food and Drug Administration’s (FDA) and other regulatory agencies’ policies and frameworks to allow for the approval of therapies based on tumour or cellular pathway biomarkers may facilitate access to new treatments for cancers for which effective therapies are lacking. The FDA’s May 2025 approval of telisotuzumab vedotin, based on the drug’s potential clinical benefit for the treatment of Hodgkin lymphoma, set a precedent for the regulatory approval of novel therapies against cancers of high unmet medical need. More flexible regulatory policies to facilitate and speed up the development of therapies against cancers of high unmet medical need will likely occur in the next 3 to 5 years. • Integrative Therapy Approaches: The development of integrative therapies to address resistance to single-agent c-MET or HGF inhibitors is rapidly progressing. Evidence suggests that c-MET or HGF inhibitors may be combined with several other modalities including immunotherapy, chemotherapy, and other kinds of targeted therapy. By 2025, a number of clinical trials evaluated the safety and preliminary activity of c-MET-directed therapies in combination with other agents. It is expected that combining therapies targeted to c-MET will continue to be evaluated to determine the effectiveness of combinations to control more recalcitrant cancers. • Industry Competition and Research: The presence of many competing companies has led to significant research and development of more effective and less toxic c-MET and HGF inhibitors. In 2025, the first c-MET-targeted antibody drug conjugate was approved in the U.S. Anticipate that, in the next 5 years, further research and the development of improved methods for the synthesis and clinical trials of oncology therapies will lead to the rapid introduction of new pharmaceutical products, enhanced company revenues and market expansion. Companies will have to develop and market therapies that improve patient outcomes to remain competitive. The challenges facing this market include: • Clinical Resistance & Tumour Heterogeneity: C-MET signaling pathway abnormalities occur in different ways in various patients, and tumour cells can turn to other signaling pathways for survival and proliferation. Due to this reason, in 2025, the focus of the clinical studies were the patient populations in which the MET alterations were defined. However, there are other ways in which the MET pathway can be activated and overexpressed, and choosing the right patients among all these variations is challenging. During the process of developing the therapy for MET alterations, it is likely that resistance is developed to that particular therapy, and in such cases, it is likely that combination or sequential therapy will be pursued. • Safety & Tolerability: C-met and HGF inhibitors are likely to have adverse effects like edema and changes in blood and liver functions. Antibody drug conjugates used for inhibiting c-met can have additional adverse effects. Due to the nature of the therapy and the complexity of patient selection, control, and management, there will be strong competition among the available therapies for oncology. • Intensive Development and Barriers To Market Access: High costs and restricted market access negatively impact the development of oncology therapies. Regulatory improvements in 2025 enhanced the approvals process, but most of these authorizations were conditional and led to the establishment of post-marketing requirements to generate additional evidence. During the next three to five years, it is expected that the therapies will encounter reimbursement and market access limitations due to the availability of other therapies, including established competitors. In the case of oncology therapies targeting MET, marketing authorization will be granted only if the therapy meets an unmet need. A meaningful improvement in clinical outcome compared to existing therapies is expected. Resistance to therapy, associated side effects, and the complexity of the diagnostic tests will continue to negatively impact the adoption of these therapies. These will be balanced against the potential benefit of the therapy. Negative reimbursement will also impact the therapy. Innovative development in oncology will increase market opportunities for MET-directed therapies. During the next three to five years, it will be critical for MET-directed therapies to demonstrate clinically meaningful improvement over existing therapies and address an unmet need. List of C-MET & HGF Inhibitor Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies c-met & hgf inhibitor market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the c-met & hgf inhibitor market companies profiled in this report include- • Exelixis • Ipsen • Pfizer • Novartis • Takeda • Merck KGaA • Takeda Pharmaceutical C-MET & HGF Inhibitor Market by Segment The study includes a forecast for the global c-met & hgf inhibitor market by type, application, and region. C-MET & HGF Inhibitor Market by Type [Value ($B) from 2019 to 2035]: • Cabozantinib • Crizotinib • Tepotinib • Others C-MET & HGF Inhibitor Market by Application [Value ($B) from 2019 to 2035]: • Hospital • Drug Store C-MET & HGF Inhibitor Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the C-MET & HGF Inhibitor Market A transition in the c-met & HGF inhibitor market has occurred from broad kinase inhibitors to antibody drug conjugates (ADCs) and biomarker-driven methods. 2025 was the year where numerous regulatory changes occurred for MET-amplified lung cancers. Various companies focused on developing companion diagnostics and partnering for MET inhibitors. Based on Lucintel’s research, we expect changes in the market constant through 2027. • United States: In May 2025, the Food and Drug Administration (FDA) granted accelerated approval to AbbVie for the use of their antibody drug conjugate, Telisotuzumab Vedotin (Emrelis) for the treatment of non-squamous non-small-cell lung cancer (NSCLC). The FDA approved Emrelis based on the results from the Phase 2 study in which 42% of patients with the NSCLC tumour expressing high levels of c-Met achieved a partial response. With this approval, we anticipate more testing to identify lung cancers with c-Met overexpression. • China: In February 2025, AstraZeneca announced in their annual report that HUTCHMED’s MET inhibitor, savolitinib (Orpathys) gained regulatory approval for the treatment of MET exon 14 skipping NSCLC. Additionally, AstraZeneca reported that savolitinib generated $100 million in global sales in 2024. As the drug is approved and commercially available in China, MET inhibitor research and clinical trials will help define China’s role in biomarker-driven therapies. • Germany: Merck KGaA continued to advance the development of tepotinib and the companion diagnostics in Europe. The 2024 oncology pipeline of Merck KGaA contained multiple projects based on biomarker-driven approaches. The ongoing clinical and diagnostic projects in Germany provide a basis for the approval of anti-HGF/MET therapy in Europe. • India: Indian pharmaceutical companies continued to manufacture and market generic crizotinib through the country’s controlled market for oncology products. The price-control policy of the Indian Department of Pharmaceuticals for over 350 essential drugs, including anti-cancer drugs, remained in place (January 2025). Over the next 3-5 years, it is expected that the manufacture and sale of generics of crizotinib will reduce the costs of MET inhibitor therapy and enhance its accessibility. • Japan: Both Merck KGaA and Taiho continued their efforts to gain market access and clinical adoption for anti-MET therapy in Japan. Tepotinib will be available in Japan for the treatment of MET Exon 14 skipped NSCLC. In the absence of a national health insurance coverage for anti-cancer therapies, the use of companion diagnostics will continue to facilitate and restrict the market access of anti-MET therapies through 2030. Features of the Global C-MET & HGF Inhibitor Market Market Size Estimates: C-MET & HGF inhibitor market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: C-MET & HGF inhibitor market size by type, application, and region in terms of value ($B). Regional Analysis: C-MET & HGF inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the C-MET & HGF inhibitor market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the C-MET & HGF inhibitor market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the c-met & hgf inhibitor market by type (cabozantinib, crizotinib, tepotinib, and others), application (hospital and drug store), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?